INmune Bio Reports Positive Phase 2 Imaging Data for XPro1595 in Early Alzheimer's Disease
I'm PortAI, I can summarize articles.
INmune Bio Inc. announced positive Phase 2 neuroimaging data for XPro1595 in early Alzheimer's disease patients with high neuroinflammation. The results, showing reduced cortical disarray, will be presented at the CTAD conference in December 2025. This AI-generated news brief is for informational purposes only and not financial advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments